Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology
June 8, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it will present preclinical data on SAN711 in a model of facial neuropathic painat the 7th Congress of the European Academy of Neurology (EAN), which is being held virtually June 19 - 22, 2021.
SAN711 is a first-in-class positive allosteric modulator of GABA-A α3 that was designed using Saniona’s ion channel drug discovery engine. While existing molecules target all GABA-A receptors indiscriminately, SAN711 selectively enhances the effects of GABA-A on α3 containing receptors. Preclinical studies have indicated that this selectivity may allow SAN711 to provide pain relief and other benefits in the central nervous system while avoiding the typical adverse effects associated with non-selective GABA-A activation such as sedation, motor instability, cognitive impairment, abuse liability and physical dependence.
At the EAN Congress, Dipak V. Amrutkar, Senior Research Scientist at Saniona, will give an ePresentation titled, “SAN711, a Selective GABAA α3 Receptor Positive Allosteric Modulator as a Novel Treatment for Trigeminal Neuralgia” on June 19, 2021, at 8:00 a.m. ET / 14.00 CEST. All presentations and related abstracts will be available on the EAN website on June 18, 2021, at 12:30 p.m. ET. Saniona also plans to continue to share its data on SAN711 and other preclinical programs in additional scientific and investor forums.
“SAN711 was discovered using Saniona’s proprietary ion channel drug discovery engine, which allows us to engineer highly selective ion channel modulators,” said Jørgen Drejer, Ph.D., Chief Scientific Officer of Saniona. “We are encouraged by the data we have generated with SAN711 in trigeminal neuralgia, an excrutiatingly painful rare disease, as well as in models of other rare neuropathic disorders, and we look forward to advancing this molecule into a Phase 1 study shortly.”
Saniona expects to begin a Phase 1 study of SAN711 in healthy volunteers in mid-2021, with data expected in early 2022.
For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: firstname.lastname@example.org
The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on 8 June 2021.
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Ceylon Graphite Announces Licence for Vein Graphite and Graphene Technologies14.6.2021 13:15:00 CEST | Press release
VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Ceylon Graphite Corp. (“Ceylon Graphite”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) is pleased to announce that it has acquired an exclusive global licence from Cambridge Advanced Materials & Innovation (“CAMI”). The licence pertains to a method of producing high quality few-layer graphene (“FLG”) and derivatives by exfoliation of high grade vein graphite produced by Ceylon Graphite (“The Technology”). This is a low-energy process which results in high-yield, few layer graphene products. This industrial process is already fully designed for large volume production, and is scalable, with modules added as demand increases. Upon completion of the licence agreement, Ceylon Graphite has gained full access to all intellectual property surrounding The Technology and know-how. Use of Ceylon’s high-grade feedstock material- vein graphite - leads to minimal to nil industrial waste during the production of graphene. The combination of uniq
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK14.6.2021 13:00:00 CEST | Press release
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted a Promising Innovative Medicine (PIM) designation for voxelotor for the potential treatment of hemolytic anemia in adults and adolescent patients 12 years of age and older with sickle cell disease (SCD). Following a review by the MHRA, PIM designations are given to promising treatments that are likely to offer a major advantage for patients and are an early indication that the treatment is a promising candidate for the Early Access to Medicines Scheme (EAMS). For the MHRA to grant a PIM designation, the product must meet each of the following three criteria: The condition should be life-threatening or
Incap Corporation: INCAP CONTINUES TO RAMP UP ITS FACTORIES IN INDIA, LOCK-DOWN EXTENDED UNTIL 21 JUNE 2021. INCAP’S PREVIOUSLY ANNOUNCED OUTLOOK FOR 2021 REMAINS UNCHANGED.14.6.2021 10:45:00 CEST | Press release
Incap Corporation 14 June 2021 at 11:45 a.m. (EEST) Stock Exchange Release Insider information INCAPCONTINUES TO RAMP UP ITS FACTORIES IN INDIA, LOCK-DOWN EXTENDED UNTIL 21 JUNE 2021. INCAP’S PREVIOUSLY ANNOUNCED OUTLOOK FOR 2021 REMAINS UNCHANGED. Incap announced on 10 May 2021 that it had temporarily closed down its factories in Tumkur until 24 May 2021. On 24 May 2021, Incap announced that the lock-down had been extended until 7 June 2021 and that it had been granted a permission for partial operation of its factories. Currently, the lock-down in Karnataka has been extended until 21 June 2021. Incap’s factories in India continue to operate according to the government guidelines and Incap is prepared to resume full operations once the restrictions are removed. The closure and the partial operations of the factories in India do not have an impact on the company’s outlook for 2021 published on 21 April 2021. Incap’s previously announced outlook for 2021: Incap estimates that its revenu
2022 PAN EUROPEAN LAUNCH OF OKUMA REELS, RODS AND COMBOS BY RAPALA VMC CORPORATION SUPPORTED BY MASSIVE MARKETING CAMPAIGN14.6.2021 10:30:00 CEST | Press release
2022 PAN EUROPEAN LAUNCH OF OKUMA REELS, RODS AND COMBOS BY RAPALA VMC CORPORATION SUPPORTED BY MASSIVE MARKETING CAMPAIGN Rapala VMC Corporation (“Rapala VMC”) announced on January 27, 2021 the acquisition of Okuma European and Russian trademarks and associated intangible assets. Rapala VMC is now pleased to announce that the largescale launch of Okuma reels, rods and combos in Europe and Russia will occur January 1, 2022. Svendsen Sport A/S (“Svendsen“) and Okuma Fishing Tackle Co Ltd (“Okuma”) have recently agreed that Okuma’s long term exclusive distribution agreement with Svendsen covering Denmark, Norway, Sweden, Iceland, UK, Ireland, France, Germany, The Netherlands, Luxembourg, Austria, Belgium, Czech Republic, Hungary, Poland and Russia (“Svendsen Territory”) will terminate effective December 31, 2021 and that Svendsen’s rights to collect pre-orders terminates September 15, 2021. To facilitate a smooth transition, Rapala VMC has agreed to acquire Svendsen’s inventories of Okum
Progress on Brunel share buyback program 202114.6.2021 10:30:00 CEST | Press release
Amsterdam, 14 June 2021 – Brunel International N.V. (Brunel; BRNL), reports the transaction details for the period 7 June 2021 through 11 June 2021 related to its share buyback program announced on 1 June 2021 for an amount up to EUR 1,977,000, and started on 3 June 2021 in order to meet obligations under its performance share plan for senior management (excluding Board of Directors). Detailed information including all individual transactions can be found on https://www.brunelinternational.net/en/share-buyback-program. DateTotal shares repurchasedAverage purchase priceTotal consideration07/06/202111,305€ 11.4980€ 129,984.8908/06/202113,004€ 11.3393€ 147,456.2609/06/202114,164€ 11.2713€ 159,646.6910/06/202113,034€ 11.3668€ 148,154.8711/06/20217,434€ 11.4107€ 84,827.14Total58,941€ 11.3685€ 670,069.85 This press release contains inside information as meant in clause 7 of the Market Abuse Regulation. Attachment Press Release Share Buyback 2021 progress
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme14.6.2021 09:35:04 CEST | Press release
Company Announcement No. 31/2021 Copenhagen, 14 June 2021 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 7 June to 11 June 2021: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement1,241,419154,300,854 7 June 202120,000131.172,623,400 8 June 202120,000130.372,607,494
bp går sammen med Aker og Statkraft om norsk havvindsatsing14.6.2021 08:30:00 CEST | Pressemelding
(Oslo, 14. juni 2021) bp har i dag besluttet å bli med Aker og Statkraft i et konsortium som vil søke konsesjon for utvikling av havvind i Norge. Partnerskapet – der bp, Statkraft og Aker Offshore Wind eier en tredjedel hver – vil aktivt søke konsesjon for å utvikle havvind i lisensområdet Sørlige Nordsjø II (SN2). Den gunstige plasseringen av SN2 gjør det mulig å levere kraft til flere omkringliggende markeder. Partnerne ser også på mulighetene for å levere fornybar kraft til elektrifisering av olje- og gassinstallasjoner. Konsortiet vil jobbe med lokale leverandører, bygge opp norsk industrikompetanse innen havvind og bidra til verdiskaping i det nordiske og europeiske kraftmarkedet. Partnerskapet kombinerer hvert av selskapenes sterke, tekniske ferdigheter og omfattende erfaring med energiprosjekter offshore som dekker hele verdikjeden fra prosjektutvikling til produksjon og levering av havbasert energi til markedet. bp har eierandeler i britisk og amerikansk havvind og mangeårig er